The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02796950|
Recruitment Status : Completed
First Posted : June 13, 2016
Last Update Posted : May 8, 2018
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion.
In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus Type 2||Drug: Acipimox||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study|
|Study Start Date :||June 2016|
|Actual Primary Completion Date :||January 20, 2017|
|Actual Study Completion Date :||January 20, 2017|
Administration of acipimox 250 mg p.o.
P.o. administration of 250 mg acipimox
Other Name: Olbetam
No Intervention: Control
- Levels of GLP-1 in plasma [ Time Frame: 9 months ]
- Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels [ Time Frame: 9 months ]
- Insulin sensitivity by measuring blood glucose after an OGTT [ Time Frame: 5 months ]
- Insulin secretion by measuring levels of insulin and c-peptid [ Time Frame: 9 months ]
- Secretion of the hormones ghrelin, leptin and GIP (gastric inhibitory polypeptide) by measuring hormone levels in plasma [ Time Frame: 9 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02796950
|University Hospital of Aarhus|
|Aarhus, Denmark, 8000|
|Principal Investigator:||Jens Otto L Jørgensen, Professor||University of Aarhus|